Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection Clinical Trial

Official title:
A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule

Status Completed

Clinical Trial Summary

Persistence of Antibody Response to N. meningitidis Group C in Children

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Meningococcal Infections
Prevention of Meningococcal Infection

Clinical Trial Details

NCT number	NCT00316654
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	February 2005
Completion date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00310674` - Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age	Phase 3
Completed	`NCT00311415` - Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children	Phase 3
Completed	`NCT00310687` - Persistence of Immune Response After Vaccination With MCC	Phase 4
Completed	`NCT00310700` - Kinetics of B Cell Response in Infants Menjugate Vaccination	Phase 4
Completed	`NCT00310713` - Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine	Phase 4